Efficacy and Safety of Subcutaneous Administration of Fremanezumab for Migraine
- Study Title
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
- Teva Identifier
- TV48125-CNS-30051 | 2015-004550-18
- ClinicalTrials.gov Identifier
- NCT02638103
- Study Status
- Completed
- Trial Condition(s)
- Migraine
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- February 26, 2016 - December 8, 2018
- Phase
- Phase 3
